Kasuki Leandro, Gadelha Mônica R
Neuroendocrinology Research Center/Endocrinology Division, Medical School and Hospital Universitário Clementino Fraga Filho, Universidade Federal Do Rio de Janeiro, Rio de Janeiro, Brazil; Neuroendocrinology Division, Instituto Estadual Do Cérebro Paulo Niemeyer, Secretaria Estadual de Saúde, Rio de Janeiro, Brazil; Endocrinology Division, Hospital Federal de Bonsucesso, Rio de Janeiro, Brazil.
Neuroendocrinology Research Center/Endocrinology Division, Medical School and Hospital Universitário Clementino Fraga Filho, Universidade Federal Do Rio de Janeiro, Rio de Janeiro, Brazil; Neuroendocrinology Division, Instituto Estadual Do Cérebro Paulo Niemeyer, Secretaria Estadual de Saúde, Rio de Janeiro, Brazil; Neuropathology and Molecular Genetics Laboratory, Instituto Estadual Do Cérebro Paulo Niemeyer, Secretaria Estadual de Saúde, Rio de Janeiro, Brazil.
Best Pract Res Clin Endocrinol Metab. 2022 Dec;36(6):101679. doi: 10.1016/j.beem.2022.101679. Epub 2022 May 27.
Acromegaly is a systemic disease associated with increased morbidity and mortality that can be prevented with adequate disease control. Three modalities of treatment (surgery, medical treatment, and radiotherapy) are available; however, a significant proportion of patients still maintain disease activity despite treatment. Therefore, there is a need for innovations in the treatment of acromegaly that include changes in the current trial and error approach and the development of new drugs. In this review, we summarize the recent innovations in the treatment of acromegaly and address the future perspectives in this field.
肢端肥大症是一种与发病率和死亡率增加相关的全身性疾病,通过充分的疾病控制可以预防。有三种治疗方式(手术、药物治疗和放疗)可供选择;然而,相当一部分患者尽管接受了治疗,仍保持疾病活动。因此,需要在肢端肥大症的治疗方面进行创新,包括改变当前的试错方法和开发新药。在本综述中,我们总结了肢端肥大症治疗方面的最新创新,并探讨了该领域的未来前景。